Cwm LLC Sells 75 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Cwm LLC lessened its holdings in Shockwave Medical, Inc. (NASDAQ:SWAV) by 26.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212 shares of the company’s stock after selling 75 shares during the quarter. Cwm LLC’s holdings in Shockwave Medical were worth $40,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in SWAV. FMR LLC grew its position in Shockwave Medical by 3.8% during the third quarter. FMR LLC now owns 2,527,893 shares of the company’s stock valued at $503,303,000 after buying an additional 92,919 shares during the period. Wellington Management Group LLP increased its stake in shares of Shockwave Medical by 33.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company’s stock worth $359,529,000 after purchasing an additional 453,048 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Shockwave Medical by 21.8% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,398,136 shares of the company’s stock worth $278,369,000 after purchasing an additional 250,352 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Shockwave Medical by 35.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 645,634 shares of the company’s stock valued at $128,546,000 after purchasing an additional 170,369 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in Shockwave Medical by 66.7% during the third quarter. Canada Pension Plan Investment Board now owns 386,321 shares of the company’s stock valued at $76,917,000 after purchasing an additional 154,637 shares during the period. 95.35% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Shockwave Medical

In other news, VP Trinh Phung sold 599 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $259.24, for a total transaction of $155,284.76. Following the completion of the transaction, the vice president now owns 31,031 shares of the company’s stock, valued at $8,044,476.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Trinh Phung sold 599 shares of Shockwave Medical stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $259.24, for a total transaction of $155,284.76. Following the completion of the sale, the vice president now directly owns 31,031 shares of the company’s stock, valued at approximately $8,044,476.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Francis sold 1,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the completion of the transaction, the director now directly owns 3,551 shares in the company, valued at approximately $887,750. The disclosure for this sale can be found here. Insiders have sold a total of 83,120 shares of company stock valued at $21,319,021 in the last 90 days. Corporate insiders own 3.40% of the company’s stock.

Shockwave Medical Price Performance

Shares of NASDAQ:SWAV opened at $330.54 on Friday. Shockwave Medical, Inc. has a 12 month low of $157.00 and a 12 month high of $331.58. The company has a current ratio of 11.76, a quick ratio of 10.73 and a debt-to-equity ratio of 1.09. The stock has a market cap of $12.40 billion, a P/E ratio of 85.41, a P/E/G ratio of 2.46 and a beta of 0.88. The company has a 50 day moving average of $307.14 and a 200 day moving average of $241.29.

Shockwave Medical (NASDAQ:SWAV) last released its quarterly earnings results on Monday, May 6th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.45. The firm had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $207.69 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The business’s quarterly revenue was up 35.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.03 earnings per share. As a group, sell-side analysts forecast that Shockwave Medical, Inc. will post 4.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Morgan Stanley restated an “equal weight” rating and issued a $335.00 target price (up from $285.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $335.00 price objective (up from $263.00) on shares of Shockwave Medical in a report on Friday, April 5th. Wells Fargo & Company lifted their target price on shares of Shockwave Medical from $200.00 to $210.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. TheStreet raised shares of Shockwave Medical from a “c+” rating to a “b” rating in a research report on Thursday, February 15th. Finally, Leerink Partnrs downgraded shares of Shockwave Medical from an “outperform” rating to a “market perform” rating in a report on Friday, April 5th. Ten equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $309.11.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.